Yükleniyor... / Loading...
This study examines the long-term effects and blood coagulation markers of P2Y12 inhibitor monotherapy (Clopidogrel, Ticagrelor or Prasugrel) after percutaneous coronary angioplasty. Patients aged 18 and over who had an acute coronary syndrome and/or coronary intervention at least 3 months earlier and completed an uneventful course of dual antiplatelet therapy may take part. The study is in Phase 3 and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥18 years * Prior (≥3 months) ACS and/or PCI * Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course * Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and/or bleeding events (defined as BARC ≥ 2) for at least 3 months * Written informed consent. Exclusion Criteria: * Unconscious patients * Unable to provide written informed consent * Under judicial protection, tutorship or curatorship * Unable to understand and follow study-related instructions or unable to comply with study protocol * Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel * Severe hepatic impairment * Haemoglobin level \<10 g/dL or platelet count \<100 000 cells/mL * Pregnant or breastfeeding women * Life expectancy less than 1 year * Active participation in another interventional trial * Need for concomitant oral anticoagulation * History of intracranial haemorrhage (anytime), transient ischemic attack or stroke within 3 months * PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization